Aelis Farma SA (AELIS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Aelis Farma SA (AELIS) has a cash flow conversion efficiency ratio of -0.635x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.88 Million ≈ $-4.54 Million USD) by net assets (€6.11 Million ≈ $7.15 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see AELIS market cap overview for the company's overall valuation and market capitalisation.
Aelis Farma SA - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Aelis Farma SA's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Aelis Farma SA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Aelis Farma SA ranked by their cash flow conversion efficiency. Explore Aelis Farma SA cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Australian Agricultural Projects Ltd
AU:AAP
|
0.124x |
|
Neuroscientific Biopharmaceuticals Ltd
AU:NSB
|
-0.029x |
|
Anugerah Kagum Karya Utama Tbk PT
JK:AKKU
|
0.000x |
|
Donegal Investment Group PLC
IR:DQ7A
|
-0.234x |
|
Lifestyle Global Enterprise
TWO:8066
|
0.102x |
|
ABERA BIOSCIENCE AB
F:8WK
|
-0.317x |
|
Tong Hua Holding Public Company Limited
BK:TH
|
-0.006x |
|
Lode Resources Ltd
AU:LDR
|
-0.055x |
Annual Cash Flow Conversion Efficiency for Aelis Farma SA (2018–2024)
The table below shows the annual cash flow conversion efficiency of Aelis Farma SA from 2018 to 2024. View Aelis Farma SA stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €10.12 Million ≈ $11.83 Million |
€-11.83 Million ≈ $-13.83 Million |
-1.170x | -22.67% |
| 2023-12-31 | €13.20 Million ≈ $15.43 Million |
€-12.59 Million ≈ $-14.71 Million |
-0.953x | -44.57% |
| 2022-12-31 | €19.79 Million ≈ $23.14 Million |
€-13.05 Million ≈ $-15.26 Million |
-0.659x | -103.12% |
| 2021-12-31 | €898.00K ≈ $1.05 Million |
€18.97 Million ≈ $22.18 Million |
21.125x | +505.27% |
| 2020-12-31 | €-710.00K ≈ $-830.06K |
€-2.48 Million ≈ $-2.90 Million |
3.490x | +245.50% |
| 2019-12-31 | €1.20 Million ≈ $1.41 Million |
€-2.89 Million ≈ $-3.38 Million |
-2.399x | -61.24% |
| 2018-12-31 | €2.38 Million ≈ $2.79 Million |
€-3.55 Million ≈ $-4.15 Million |
-1.488x | -- |
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company is developing signaling-specific inhibitors of the CB1 receptors, such as AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; an… Read more